3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
393
Brain Neoplasms
162
Glioma
156
Gliosarcoma
130
Astrocytoma
111
Central Nervous System Neoplasms
109
Melanoma
75
Oligodendroglioma
73
Neuroblastoma
44
Neoplasms
33
Medulloblastoma
33
Neoplasm Metastasis
29
Recurrence
28
Ependymoma
25
Sarcoma
23
Sarcoma, Ewing
22
Rhabdomyosarcoma
18
Small Cell Lung Carcinoma
16
Lymphoma
16
Carcinoma, Non-Small-Cell Lung
16
Diffuse Intrinsic Pontine Glioma
15
Lung Neoplasms
14
Breast Neoplasms
14
Ovarian Neoplasms
13
Neuroendocrine Tumors
13
Choroid Plexus Neoplasms
13
Optic Nerve Glioma
11
Neuroectodermal Tumors, Primitive
11
Spinal Cord Neoplasms
10
Rhabdoid Tumor
10
Interventions
Doxorubicin
3
lentiviral minigene vaccine of COVID-19 coronavirus
1
eltrombopag
1
camrelizumab
1
apatinib
1
Vinorelbine
1
Trabectedin
1
Temozolomide
1
Sodium Chloride
1
Methotrexate
1
Irinotecan
1
FANG vaccine
1
Dexamethasone
1
Cisplatin
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Connective and Soft Tissue
×
Temozolomide
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts